LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Endo investigation page on our website at www.glancylaw.com/case/endo-international-plc.
On June 8, 2017, the U.S. Food and Drug Administration (the “FDA”) instructed Endo to pull its powerful opioid painkiller Opana ER off the U.S. market. According to the FDA, Opana’s “high risk of abuse and potential to help spread HIV and hepatitis C” necessitated its removal from the market.
On this news, shares of Endo have fallen over 14% during intraday trading on June 9, 2017.
If you purchased Endo securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.